Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryCarolina Behavioral Health VNS Coverage | OpenPaye…
    Ask Trek AI about this page
    ModifiedCarolina Behavioral Health Alliance (CBHA)Policy CP.MP.12

    Vagus Nerve Stimulation

    Customize your policy alerts

    Sign up for carolinabehavioralhealth Policy CP.MP.12 alerts

    Get alerted when Policy CP.MP.12 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of implantable and transcutaneous vagus nerve stimulation for epilepsy, seizures, and other proposed indications. Implantable VNS may be medically necessary for medically refractory seizures meeting specified clinical criteria; other indications and transcutaneous approaches are not supported.

    Policy Summary
    PayerCarolina Behavioral Health Alliance (CBHA)
    PolicyVagus Nerve Stimulation
    Policy CodePolicy CP.MP.12
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the qualifying seizure type, failure of adherent therapy with at least two anti-seizure drugs, ongoing impact on activities of daily living, epilepsy surgery status, and use of an FDA-approved device.
    SourceLink
    POLICY UPDATE CHANGES

    The criteria were revised to specify implantable vagus nerve stimulation and to add Lennox-Gastaut syndrome as an eligible condition.

    Cluster headaches or migraines were added to the applicable clinical criteria.

    Aspire SR Model 106 was removed as a medically necessary VNS option.

    HCPCS code C1827 was added to the codes considered medically necessary or supportive of coverage criteria.

    The ICD-10 diagnosis code table was removed from the policy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Anti-seizure drugs that must have failed
    7CPT codes supporting coverage criteria
    15HCPCS codes supporting coverage criteria
    1HCPCS codes not supporting coverage criteria
    C1827Added HCPCS code

    Implantable and Transcutaneous VNS Coverage

    Initial implantable VNS therapy

    Implantable VNS is medically necessary when all of the following are met:

    Implantable VNS medical necessity

    • Qualifying seizure diagnosis: Diagnosis of focal-onset (formerly partial-onset) seizures or generalized-onset seizures, including Lennox-Gastaut syndrome.
    • Intractable epilepsy

      • Medication failure: Failure of adherent therapy with at least two anti-seizure drugs.at least 2 anti-seizure drugs
      • Ongoing functional impact: Continued seizures have a major impact on activities of daily living.major impact on activities of daily living
    • Epilepsy surgery status: Member is not a suitable candidate for epilepsy surgery, is opposed to epilepsy surgery, or has failed epilepsy surgery.
    • Device requirement: Request is for an FDA-approved device.FDA-approved device

      The policy background notes that VNS is not currently FDA-approved for generalized seizures, although the coverage criterion requires an FDA-approved device.

    The safety and efficacy of VNS have not been proven for refractory major depression or bipolar disorder, headaches including cluster headaches or migraines, or other proposed indications. Unsupported uses also include cognitive impairment associated with Alzheimer’s disease, addiction, anxiety disorders, autism, eating disorders, cancer, Crohn’s disease, essential tremor, fibromyalgia, heart failure, impaired glucose tolerance or pre-diabetes, inflammation, overweight or obesity, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, Prader-Willi syndrome, Sjogren’s syndrome, rheumatoid arthritis, schizophrenia, sleep disorders, stroke, tinnitus, Tourette’s syndrome, and traumatic brain injury.

    Current research does not support transcutaneous VNS or active auricular transcutaneous electrical nerve stimulation because large, high-quality studies establishing their safety and efficacy are lacking.

    Implantable VNS is not medically necessary for medically refractory seizures when required criteria are absent. The member must have a qualifying diagnosis of focal-onset or generalized-onset seizures, including Lennox-Gastaut syndrome; failure of adherent therapy with at least two anti-seizure drugs; continued seizures with a major impact on activities of daily living; an epilepsy-surgery status indicating the member is not a suitable candidate, is opposed to surgery, or has failed surgery; and a request for an FDA-approved device.

    Aspire SR Model 106 was removed as a medically necessary VNS option. Requests should therefore be evaluated under the current implantable VNS criteria and applicable device requirements rather than treating this model as a supported medically necessary option.

    Coverage-Supporting Codes

    CPT Codes that Support Coverage CriteriaCPTCovered
    61885Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array
    61886Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to two or more electrode arrays
    61888Revision or removal of cranial neurostimulator pulse generator or receiver
    64553Percutaneous implantation of neurostimulator electrode array; cranial nerve
    64568Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator
    64569Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator
    64570Removal of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator
    HCPCS Codes that Support Coverage CriteriaHCPCSCovered
    C1767Generator, neurostimulator (implantable), nonrechargeable
    C1778Lead, neurostimulator (implantable)
    C1816Receiver and/or transmitter, neurostimulator (implantable)
    C1827Generator, neurostimulator (implantable), nonrechargeable, with implantable stimulation lead and external paired stimulation controller
    C1883Adaptor/extension, pacing lead or neurostimulator lead (implantable)
    L8680Implantable neurostimulator electrode, each
    L8681Patient programmer (external) for use with implantable programmable
    L8682Implantable neurostimulator radiofrequency receiver
    L8683Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver
    L8685Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
    1–10 of 14
    1/2
    HCPCS Codes that Do Not Support Coverage CriteriaHCPCSNot Covered
    K1020Noninvasive vagus nerve stimulator

    Documentation and Coverage Review Requirements

    Documentation Required

    Required Clinical Elements

    Document the clinical elements needed to establish that the member has medically refractory seizures and meets the policy criteria for implantable VNS. The request must support the qualifying seizure type, intractable epilepsy, treatment history, ongoing functional impact, surgical history or candidacy, and use of an FDA-approved device.

    • Seizure type: focal-onset seizures or generalized-onset seizures, including Lennox-Gastaut syndrome.
    • Intractable epilepsy: failure of adherent therapy with at least two anti-seizure drugs and continued seizures that have a major impact on activities of daily living.
    • Document that the member is not a suitable candidate for, is opposed to, or has failed epilepsy surgery.
    • Identify the requested device and confirm that it is FDA approved.
    Denial Risk

    Two Anti-Seizure Drugs Must Have Failed

    Vagus Nerve Stimulation Overview

    Vagus nerve stimulation delivers chronic intermittent electrical pulses to the cervical portion of the left vagus nerve through an implanted neurocybernetic prosthesis. The pulse generator is placed under the skin of the left chest, and a lead is positioned through an incision in the neck, generally during outpatient surgery under general anesthesia. The policy’s evidence summary describes potential benefit for medically refractory focal-onset seizures in patients who are not surgical candidates or whose epilepsy surgery has failed, while evidence for other indications and nonimplantable approaches remains limited or investigational.

    Key VNS Terms and Devices

    Vagus nerve stimulation (VNS)
    ModalityImplantable neurocybernetic prosthesis
    Stimulation siteCervical portion of the left vagus nerve
    Stimulation pattern and purposeChronic intermittent electrical stimulation designed to treat medically refractory epilepsy
    Transcutaneous vagus nerve stimulation (tVNS)
    ModalityNoninvasive, transcutaneous alternative to implantable VNS
    Application sitesExternally applied to the ear or superficially to the cervical region near the vagus nerve
    Delivery method
    Policy Summary
    PayerCarolina Behavioral Health Alliance (CBHA)
    PolicyVagus Nerve Stimulation
    Policy CodePolicy CP.MP.12
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the qualifying seizure type, failure of adherent therapy with at least two anti-seizure drugs, ongoing impact on activities of daily living, epilepsy surgery status, and use of an FDA-approved device.
    SourceLink
    On This Page
    Implantable and Transcutaneous VNS CoverageCoverage-Supporting CodesDocumentation and Coverage Review RequirementsVagus Nerve Stimulation OverviewKey VNS Terms and Devices

    Verify and document failure of adherent therapy with at least two anti-seizure drugs before requesting implantable VNS for medically refractory seizures.

    • Include the names of the anti-seizure drugs tried, treatment adherence, treatment duration or history when available, and the outcome or reason each therapy failed.
    • Failure of fewer than two anti-seizure drugs does not satisfy the intractable-epilepsy criterion.
    Denial Risk

    Implantable VNS Coverage Criteria

    Confirm that all implantable VNS medical-necessity criteria are met. Requests may be denied when the seizure type, medication history, ongoing functional impact, epilepsy-surgery status, or device approval requirements are not established.

    • Diagnosis must be focal-onset or generalized-onset seizures, including Lennox-Gastaut syndrome.
    • Document adherent therapy failure with at least two anti-seizure drugs and continued seizures with a major impact on activities of daily living.
    • The member must not be a suitable candidate for, be opposed to, or have failed epilepsy surgery.
    • The request must be for an FDA-approved implantable VNS device.
    Denial Risk

    Unproven Non-Epilepsy Indications

    Do not submit VNS requests for conditions for which safety and efficacy have not been proven under this policy. Unsupported indications include, but are not limited to, the following conditions.

    • Refractory or treatment-resistant major depression; bipolar disorder; headaches, including cluster headaches or migraines; cognitive impairment associated with Alzheimer's disease; addiction; anxiety disorders; autism; eating disorders; and cancer.
    • Crohn's disease; essential tremor; fibromyalgia; heart failure; impaired glucose tolerance or pre-diabetes; inflammation; overweight or obesity; obsessive-compulsive disorder; panic disorder; post-traumatic stress disorder; and Prader-Willi syndrome.
    • Sjogren's syndrome; rheumatoid arthritis; schizophrenia; sleep disorders; stroke; tinnitus; Tourette's syndrome; and traumatic brain injury.
    Denial Risk

    Unsupported Transcutaneous Stimulation

    Do not represent transcutaneous VNS or active auricular transcutaneous electrical nerve stimulation as supported indications. Current research does not support these uses because large, high-quality studies are lacking.

    • This limitation applies to transcutaneous VNS and active auricular transcutaneous electrical nerve stimulation.
    • Requests for these noninvasive stimulation approaches may be denied as unsupported by current evidence.
    Billing Rule

    K1020 Does Not Support Coverage

    HCPCS code K1020 does not establish that a noninvasive VNS service or device meets the policy's coverage criteria. Coding the device under K1020 does not substitute for meeting the applicable medical-necessity requirements.

    • K1020: Noninvasive vagus nerve stimulator.
    • The code is listed as not supporting coverage criteria.
    Uses a specially designed device, such as gammaCore or Phoenix, to apply stimulation
    AspireSR Model 106
    Device typeImplantable VNS device modification manufactured by Cyberonics
    Detection capabilityDetects tachycardia heart rates that may be associated with an impending seizure
    Automatic stimulationAutomatically delivers stimulation to the vagus nerve in AutoStim mode without patient interaction
    AutoStim precautionAutoStim mode should not be used with significant arrhythmias treated with pacemakers, implantable defibrillators, beta-blockers, or other treatments affecting intrinsic heart rate